Sei Investments Co. Buys New Shares in Atea Pharmaceuticals, Inc. $AVIR

Sei Investments Co. purchased a new stake in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 156,384 shares of the company’s stock, valued at approximately $841,000. Sei Investments Co. owned approximately 0.20% of Atea Pharmaceuticals as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. Prudential Financial Inc. bought a new position in shares of Atea Pharmaceuticals during the 2nd quarter valued at about $36,000. RFG Advisory LLC purchased a new position in shares of Atea Pharmaceuticals during the 4th quarter valued at about $53,000. Jump Financial LLC lifted its position in Atea Pharmaceuticals by 36.5% in the 4th quarter. Jump Financial LLC now owns 19,113 shares of the company’s stock worth $68,000 after buying an additional 5,106 shares during the last quarter. Squarepoint Ops LLC bought a new stake in Atea Pharmaceuticals in the 4th quarter worth approximately $69,000. Finally, BNP Paribas Financial Markets lifted its position in Atea Pharmaceuticals by 57.7% in the 3rd quarter. BNP Paribas Financial Markets now owns 19,913 shares of the company’s stock worth $58,000 after buying an additional 7,286 shares during the last quarter. Institutional investors own 86.67% of the company’s stock.

Atea Pharmaceuticals Trading Up 0.2%

Shares of NASDAQ:AVIR opened at $5.07 on Friday. The stock has a market capitalization of $405.75 million, a P/E ratio of -2.44 and a beta of 0.30. The stock’s 50-day moving average price is $4.68 and its 200-day moving average price is $4.92. Atea Pharmaceuticals, Inc. has a 12-month low of $2.78 and a 12-month high of $6.45.

Atea Pharmaceuticals (NASDAQ:AVIR) last released its earnings results on Wednesday, August 12th. The company reported ($0.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.56) by $0.15. As a group, research analysts predict that Atea Pharmaceuticals, Inc. will post -1.93 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on AVIR shares. Morgan Stanley increased their price target on shares of Atea Pharmaceuticals from $6.00 to $7.00 and gave the company an “equal weight” rating in a research report on Thursday. Weiss Ratings restated a “sell (d-)” rating on shares of Atea Pharmaceuticals in a report on Friday, July 17th. One research analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and a consensus price target of $7.00.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of oral antiviral therapeutics targeting RNA viruses. The company’s lead program, AT-527, is a direct-acting nucleotide prodrug licensed from Roche and is being evaluated as a potential treatment for coronavirus disease 2019 (COVID-19). In addition to its COVID-19 efforts, Atea’s pipeline includes other small-molecule candidates for hepatitis C virus and emerging RNA pathogens, leveraging its proprietary nucleotide chemistry platform to address significant unmet medical needs in infectious diseases.

Founded in 2014 and headquartered in Cambridge, Massachusetts, Atea operates research laboratories in the Greater Boston area and conducts clinical studies across North America, Europe and parts of Asia.